Support for Orphan Drug Designation (ODD) in Europe

Case studies - 1 March 2018

Support for Orphan Drug Designation (ODD) in Europe


BlueReg (BR) was engaged to assist a start-up company with the preparation of their orphan drug designation application dossier in Europe and to provide regulatory support during the procedure. 



  • Timelines: the client contacted BR a short time ahead of the planned submission date requesting a review and update of their draft ODD dossier. At this time, the client had been in contact with the EMA but had not followed up them for some time.
  • Regulatory context: at the time the project started, a new EU guideline laying down new requirements for ODD, in particular to justify significant benefit over existing therapies that would directly impact this application, was issued.

Download the
Case Study

    BlueReg undertakes to comply with the regulations in force applicable to the processing of personal data and, in particular, Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 applicable as from 25 May 2018 (hereinafter, "the General Data Protection Regulations" or GPDR) and the national laws resulting therefrom.
    Any inquiries, correction or declaration of event related to personal data processed should be sent to: our contact page
    Learn more

    Thank you for your reply

    You can download the file below